QIAGEN Reports Strong First Quarter 2010 Results

Qiagen N.V. / QIAGEN Reports Strong First Quarter 2010 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. * 20% Revenue growth * 11% Organic growth * 22% Net income growth (adj.) * $0.20 Adjusted EPS Venlo, The Netherlands, May 3, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010. First Quarter 2010 Results +---------------------------------------------------------------------------+ |QIAGEN's First Quarter 2010       | +---------------------------------------------------------------------------+ |in US$ millions, except per share information Q1 2010 Q1 2009 Growth| +---------------------------------------------------------------------------+ |        | | | |Net sales 264.4 220.9 20%| | | |Operating income, adjusted 73.6 59.1 24%| | | |Net income, adjusted 49.3 40.3 22%| | | |EPS, adjusted( )(US$) 0.20 0.20   | | | |        | +---------------------------------------------------------------------------+ For information on the adjusted figures, please refer to the reconciliation table accompanying this release. The Company reported that consolidated net sales for its first quarter of 2010 increased 20% to $264.4 million from $220.9 million for the same quarter of 2009. Excluding the favorable impact from foreign currency exchange rates, net sales for the first quarter 2010 would have increased by 14% from the first quarter of 2009. Reported operating income for the quarter increased 21% to $44.7 million from $37.0 million in the same quarter of 2009, and net income for the quarter increased 34% to $33.0 million from $24.7 million in the same quarter of 2009. Diluted earnings per share for the first quarter increased 17% to $0.14 in 2010 (based on 241.9 million weighted average shares and share equivalents outstanding) from $0.12 in 2009 (based on 203.2 million weighted average shares and share equivalents outstanding). On an adjusted basis, first quarter operating income increased 24% to $73.6 million in 2010 from $59.1 million in 2009, and first quarter adjusted net income increased 22% to $49.3 million in 2010 from $40.3 million in 2009. Adjusted diluted earnings per share were $0.20 in the first quarters of both, 2010 and 2009. QIAGEN's first quarter 2010 results include the results of operations from the Company's recent acquisitions, the most significant of which were SABiosciences Corporation, acquired in December 2009, and DxS Ltd., acquired in September 2009. Reconciliations of reported results determined in accordance with generally accepted accounting principles (GAAP) to adjusted results are included in the tables accompanying this release. "QIAGEN experienced a successful start into 2010," said Peer Schatz, QIAGEN's Chief Executive Officer. "We recorded strong revenue and adjusted net income growth and continued to see exciting momentum in our strategic position. We launched 14 new products in the area of Sample & Assay Technologies and recorded once again an excellent 4% of sales from products launched within the last 12 months. We are also managing an exceptionally strong pipeline of new products and are preparing for the 2010 launches of many strategically important products including the QIAensemble and QIAsymphony-RGQ platforms in Europe together with their broad menu of regulated assays for prevention, profiling and personalized healthcare. The first quarter of 2010 was a quarter of very important strategic moves, including in molecular diagnostics. In the field of prevention we extended our support of a cervical cancer screening program for underprivileged women with the Cancer Foundation in China. In the area of profiling we established an agreement for a respiratory pathogen multiplex assay with Celera and in personalized healthcare we were able to acquire an exclusive license for biomarker PI3K from John Hopkins University, a gene discussed as a key biomarker for use in companion diagnostics with certain cancer treatments and entered into an agreement to develop a companion diagnostic with the pharmaceutical company Pfizer for brain tumor patients. In the field of point of need testing we expanded our instrumentation platform with a portable, battery operated, "ultra-fast time to result", multiplex UV and fluorescence optical measurement device through the acquisition of ESE GmbH for use in medical emergency and critical care testing and in industrial environments. In addition, we experienced good growth in product sales to our customers in academia, the pharmaceutical industry and in applied markets. We are very well positioned to take advantage of the growth opportunities we are seeing in our target markets and are fully on track to achieve our annual targets." "We are pleased with our financial performance in this first quarter of 2010. Reported revenues were at the high end of, and adjusted earnings per share exceeded our expectations for the first quarter of 2010," said Roland Sackers, QIAGEN's Chief Financial Officer. "Revenue growth for the first quarter was 20% fueled by a strong organic growth of 11% and a positive contribution of 5% from acquisitions. In addition we saw high growth rates of 24% in our adjusted operating income and of 22% in our adjusted net income. Our consumable portfolio represented approximately 86% of our total net sales and contributed 15% growth (10% at constant exchange rates). QIAGEN's instrumentation products contributed approximately 14% of our total net sales and continued to show high growth rates of 46% (37% at constant exchange rates). Highlights within our instrumentation portfolio were sample and assay technology automation platforms such as our EZ1 Advanced XL, the QIAsymphony, the QIAgility, the Pyromark and the Rotor-Gene Q. The largest revenue share we recorded in the first quarter 2010 was in sales to customers in molecular diagnostics (approximately 45% of total revenues) followed by sales to customers in academia (approximately 27% of total revenues), in pharma (approximately 21% of total revenues) and in applied testing (approximately 7% of total revenues)." "We are reiterating our guidance for fiscal year 2010 based on foreign currency exchange rates as of January 31, 2010, with expected revenues between $1,120 and $1,170 million and adjusted diluted earnings per share between $0.90 and $0.96." QIAGEN - Sample and Assay Technologies Highlights * QIAGEN acquired ESE GmbH, a developer and manufacturer of portable, battery operated, "ultra-fast time to result", multiplex UV and fluorescence optical measurement devices which enable low-throughput molecular testing in practices, emergency rooms, remote field areas, and other settings where a laboratory infrastructure is not accessible and fast turnaround is required. * QIAGEN and Pfizer entered into an agreement to develop a companion diagnostic assay for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Glioblastoma multiforme is the most common malignant primary brain tumor in adults and occurs in around 25,000 patients worldwide each year. Pfizer's investigational drug PF-04948568 (CDX-110) is a peptide vaccine which targets the tumor-specific Epidermal Growth Factor Receptor variant III (EGFRvIII), a mutated form of the epidermal growth factor receptor that is only present in cancer cells and occurs in 25-40 percent of GBM tumors. The QIAGEN assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment. * QIAGEN acquired a global and exclusive license for biomarker PI3K from John Hopkins University and intends to develop PCR and real time-PCR assays for companion diagnostic use with certain cancer treatments. A number of studies suggest that mutations in the PI3K oncogene are indicative for successful antibody treatment of patients suffering from lung, breast and other cancers. The license includes all countries and allows QIAGEN to enter partnerships with pharmaceutical companies to develop and market tests for new cancer drug candidates. * QIAGEN launched 14 new products in the area of Sample & Assay Technologies including the second module of the QIAsymphony, the QIAsymphony AS for automated assay setup in combination with the QIAsymphony SP, the QIAxtractor, a high throughput nucleic acid purification system and miScript PCR products for use in real time PCR set ups while working with miRNA. In addition QIAGEN launched a number of molecular diagnostic assays including CE labeled artus real time PCR assays for the detection of the BK virus, the VZV (varicella-zoster virus) and the CE labeled QIAsymphony AXpH DNA Kit for DNA extraction from PreservCyt Liquid Cytology samples on the QIAsymphony for HPV testing. Conference Call and Webcast Details Detailed information on QIAGEN's business and financial performance will be presented during its conference call on May 4, 2010 at 9:30am ET (3:30pm CET). The corresponding presentation slides will be available for download on the Company's website at www.qiagen.com/goto/ConferenceCall < http://www.qiagen.com/goto/ConferenceCall>. A webcast of the conference call will also be available at www.qiagen.com/goto/ConferenceCall < http://www.qiagen.com/goto/ConferenceCall>. Use of Adjusted Results QIAGEN has regularly reported adjusted results to give additional insight into its financial performance and has also considered results on a constant currencies basis. Adjusted results should be considered in addition to the reported results prepared in accordance with generally accepted accounting principles, but should not be considered as a substitute. The Company believes certain items should be excluded from adjusted results to provide additional insight into the Company's performance when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Company's competitors and its own prior periods. Reconciliations of reported results to adjusted results are included in the tables accompanying this release. About QIAGEN QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/. Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of the applied testing markets, personal healthcare markets, clinical research markets and proteomics markets, women's health/HPV testing markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, changing relationships with customers, suppliers and strategic partners, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate and protect its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). ### QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited)   Three months (in US$ thousands, except per share data) ended March 31, --------------------   2010 2009 Net sales 264,364 220,933    Cost of sales 91,152 74,484 -------------------- Gross profit 173,212 146,449 -------------------- Operating expenses:    Research and development 31,597 25,643    Sales and marketing 64,436 56,098    General and administrative, integration and other 26,340 23,788    Acquisition-related intangible amortization 6,158 3,891 -------------------- Total operating expenses 128,531 109,420 -------------------- Income from operations 44,681 37,029 -------------------- Other income (expense):    Interest income 689 1,185    Interest expense (6,254) (7,431)    Other income, net 2,235 1,781 -------------------- Total other expense (3,330) (4,465) -------------------- Income before provision for income taxes 41,351 32,564 Provision for income taxes 8,337 7,880 -------------------- Net income 33,014 24,684 -------------------- Weighted average number of diluted common shares 241,924 203,168 Diluted net income per common share $ 0.14 $ 0.12 Diluted net income per common share, adjusted $ 0.20 $ 0.20 QIAGEN N.V. CONDENSED CONSOLIDATED BALANCE SHEETS (in US$ thousands, except par value) March 31, December 31,   2010 2009 Assets (unaudited) Current Assets: Cash and cash equivalents 794,770 825,557 Short-term investments 94,000 40,000 Accounts receivable, net 190,220 193,737 Income taxes receivable 12,706 12,907 Inventories, net 125,118 130,851 Prepaid expenses and other 86,819 96,893 Deferred income taxes 27,978 33,525 Total current assets 1,331,611 1,333,470 Long-Term Assets: Property, plant and equipment, net 312,424 317,467 Goodwill 1,328,160 1,337,064 Intangible assets, net 745,800 752,296 Deferred income taxes 28,142 26,387 Other assets 34,062 29,780 Total long-term assets 2,448,588 2,462,994 Total assets 3,780,199 3,796,464 Liabilities and Shareholders' Equity Current Liabilities: Accounts payable 45,572 43,775 Accrued and other liabilities 209,479 248,699 Income taxes payable 12,212 10,727 Current portion of long-term debt 50,000 50,000 Current portion of capital lease obligations 3,380 3,417 Deferred income taxes 17,497 18,912 Total current liabilities 338,140 375,530 Long-Term Liabilities: Long-term debt, net of current portion 870,000 870,000 Capital lease obligations, net of current portion 26,818 27,554 Deferred income taxes 209,115 212,690 Other 25,061 19,521 Total long-term liabilities 1,130,994 1,129,765 Shareholders' Equity: Common shares, EUR .01 par value: Authorized--410,000 shares Issued and outstanding--232,384 shares in 2010 and 232,074 shares in 2009 2,715 2,711 Additional paid-in-capital 1,629,486 1,622,733 Retained earnings 648,593 615,579 Accumulated other comprehensive income 30,271 50,146 Total shareholders' equity 2,311,065 2,291,169 Total liabilities and shareholders' equity 3,780,199 3,796,464 QIAGEN N.V. RECONCILIATION OF REPORTED TO ADJUSTED FIGURES (unaudited) Three months ended March 31, 2010 (in US$ millions, except EPS data)       Operating Pre-tax     Diluted   Net Gross Income Net Sales Profit Income Income Tax Income EPS* ---------------------------------------------------------------- Reported results 264.4 173.2 44.7 41.3 (8.3) 33.0 $ 0.14 Adjustments: Business integration, acquisition related and restructuring costs - 0.8 5.1 5.1 (1.7) 3.4 0.01 Purchased intangibles amortization - 15.1 21.2 21.2 (10.2) 11.0 0.04 Share-based compensation - 0.1 2.6 2.6 (0.7) 1.9 0.01 ---------------------------------------------------------------- Total adjustments - 16.0 28.9 28.9 (12.6) 16.3 0.06 ---------------------------------------------------------------- Adjusted results 264.4 189.2 73.6 70.2 (20.9) 49.3 $ 0.20 ---------------------------------------------------------------- * Using 241.9 M diluted shares Three months ended March 31, 2009 (in US$ millions, except EPS data)       Operating Pre-tax     Diluted   Net Gross Income Net Sales Profit Income Income Tax Income EPS* ---------------------------------------------------------------- Reported results 220.9 146.4 37.0 32.6 (7.9) 24.7 $ 0.12 Adjustments: Business integration, acquisition related and restructuring costs - 0.3 3.0 3.0 (0.9) 2.1 0.01 Purchased intangible amortization - 13.0 16.9 16.9 (5.9) 11.0 0.06 Share-based compensation - 0.2 2.2 2.2 (0.7) 1.5 0.01 Asset impairment - - - 1.5 (0.5) 1.0 - ---------------------------------------------------------------- Total adjustments - 13.5 22.1 23.6 (8.0) 15.6 0.08 ---------------------------------------------------------------- Adjusted results 220.9 159.9 59.1 56.2 (15.9) 40.3 $ 0.20 ---------------------------------------------------------------- * Using 203.2 M diluted shares Contacts: QIAGEN Investor Relations: QIAGEN Public Relations: Dr. Solveigh Mähler Dr. Thomas Theuringer Director Investor Relations Director Public Relations +49 2103 29 11710 +49 2103 29 11826 email: solveigh.maehler@qiagen.com email: thomas.theuringer@qiagen.com <mailto:solveigh.maehler@qiagen.com> <mailto:thomas.theuringer@qiagen.com> Albert F. Fleury Director Corporate Finance and Investor Relations NA +1 301 944 7028 email: albert.fleury@qiagen.com <mailto:albert.fleury@qiagen.com> [HUG#1411313] --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands ISIN: NL0000240000; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse;

Companies

Qiagen NV (0H1Z)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today